Abstract
The 2019-2020 Northern Hemisphere influenza vaccine includes antigens from 3c3.A H3N2 viruses; however, over half of circulating H3N2 viruses belong to subclade 3c2.A1b. Here, we analyzed antibody responses elicited by the egg-adapted 3c3.A H3N2 vaccine strain in ferrets and humans. We found that this vaccine strain elicits antibodies that have reduced reactivity to a wild-type 3c3.A strain and very limited reactivity to 3c2.A strains, including the currently circulating 3c2.A1b strain.
Competing Interest Statement
S.E.H. reports receiving consulting fees from Sanofi Pasteur, Lumen, Novavax, and Merck.
Clinical Trial
The study involved collecting blood before and after influenza vaccination. Influenza vaccines were given to the donors as part of their routine standard of care (vaccines were not given by investigators of this study, but rather by a University clinic). Therefore, the study only involved blood collection; the IRB approved the study but it was not registered at ClinicalTrials.gov.
Funding Statement
This work was funded by institutional funds from the University of Pennsylvania and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (R01AI113047 (S.E.H.), R01AI108686 (S.E.H.), and HHSN272201400005C (S.E.H.). S.E.H. holds an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is presented in the manuscript.
